---
title: "Allogene Therapeutics, Inc. (ALLO.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/ALLO.US.md"
symbol: "ALLO.US"
name: "Allogene Therapeutics, Inc."
industry: "生物技術"
---

# Allogene Therapeutics, Inc. (ALLO.US)

| Item | Detail |
|------|--------|
| Industry | 生物技術 |
| Location | 美股市場 |
| Website | [allogene.com](https://allogene.com) |

## Company Profile

Allogene Therapeutics, Inc.是一家臨床階段的免疫腫瘤學公司，開發和商業化基因工程同種異體 T 細胞療法，用于治療癌症和自身免疫疾病。它開發、生產和商業化 UCART19，這是一種針對 R/R CD19 陽性 B 細胞急性淋巴細胞白血病（ALL）患者的同種異體抗 CD19 嵌合抗原受體（CAR）T 細胞產品候選藥物。該公司還開發了 cemacabtagene ansegedleucel，這是一種針對 CD19 的工程化同種異體 CAR T 細胞產品候選藥物，用于治療大 B 細胞淋巴瘤

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:14.000Z

**Overall: D (0.75)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 236 / 403 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -100.00% |  |
| Net Profit YoY | 25.20% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.52 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 478.68M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 0.00 |  |


**Multi Score**: D

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -54.43% | E |
| Profit Margin | 0.00% | D |
| Gross Margin | 0.00% | E |

#### Growth Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -100.00% | E |
| Net Profit YoY | 25.20% | B |
| Total Assets YoY | -25.35% | E |
| Net Assets YoY | -32.00% | E |

#### Cash Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 0.00% | D |
| OCF YoY | -100.00% | E |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.00 | E |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 28.30% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Allogene Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-54.43%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "E",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-100.00%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "25.20%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-25.35%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-32.00%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "E",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-100.00%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "28.30%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ADMA生物制藥 (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | Rigel制藥 (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.26 | 267/604 | - | - | - |
| PB | 1.52 | 138/604 | 1.00 | 0.80 | 0.71 |
| PS (TTM) | 11631.14 | - | 11631.14 | 11631.14 | 11631.14 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-20T05:00:00.000Z

Total Analysts: **16**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 10 | 63% |
| Overweight | 3 | 19% |
| Hold | 1 | 6% |
| Underweight | 1 | 6% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.04 |
| Highest Target | 14.00 |
| Lowest Target | 1.60 |

## References

- [Company Overview](https://longbridge.com/en/quote/ALLO.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/ALLO.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/ALLO.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.